Cspc Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd.

29 YRS

Hebei, China

CNY 177.8 Million

225774 m²

Over 1000 people

Main Products: L-Ascorbic Acid / Sodium L-Ascorbate / L-Ascorbic acid 2-Phosphate

Hebei, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

CRO

Total Employees

1000+ People

Plant Size

339 Acres

Production Experience

29+ Years

Registered Capital

CNY 177.8 Million

MAIN
PRODUCTS

1/3

Ascorbic acid

CAS: 50-81-7

Packing: 25 KG/Carton; 500 KG/Jumbo Bag; 1000 KG/Jumbo Bag

Lead Time: In Stock

Inquiry

1/3

Sodium Ascorbate

CAS: 134-03-2

Packing: 25 KG/Carton

Lead Time: In Stock

Inquiry

1/3

L- Ascorbate-2-Mono Phosphate

CAS: 23313-12-4

Packing: 25 KG/Carton; 20 KG/Woven Bag; 1000 KG/Jumbo Bag

Lead Time: In Stock

Inquiry

ABOUT US

CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd.

CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs. The group’s total assets are 50 billion RMB, with 27000 employees. Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI, and also the first pharmaceutical stock in the 50-year history of HSI. On March 22, 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group. At present, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin, and other provinces and cities. The products are sold in more than 100 countries and regions around the world, and 36 single varieties sold over 100 million RMB. CSPC has already completed the complete transformation from raw materials to preparations, from generic drugs to innovative drugs. At present, the sales revenue of innovative drugs has accounted for more than half of the group, becoming the mainstay of the group.